Zacks Investment Research
24 Jun 2026, 14:55 UTC · 15w ago
Impact · against what's priced in
Veradermics (MANE) shows positive momentum driven by a strong analyst consensus price target and upward earnings revisions. While analyst targets alone are not definitive catalysts, the convergence of price targets and improving fundamental estimates suggests potential upside.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish
Wall Street analysts have a mean price target of $132.25 for Veradermics (MANE), implying a potential upside of 27.7% from its current price of $103.6.
So whatPositive analyst consensus on price targets typically attracts buyers and creates upward pressure on the stock price.
More positive than 79% of claims this week
There is a positive trend in earnings estimate revisions for Veradermics, indicating analysts expect the company to report better earnings than previously estimated.
Continue reading
5 related stories
Wall Street analysts maintain a mean price target of $132.25, representing a 27.7% upside from the current $103.6 price, supported by a positive trend in earnings estimate revisions.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The stock has gained value and analysts suggest a potential upside of 27.7% with positive earnings estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
1d ago
+26.4%
Price agrees with the score
$130.90 vs $103.60 close before publication (Jun 23) · not market-adjusted
MANE chart →
